No, you cannot get rid of HSV-2. Once the virus infects you, it stays in your body for life. No medication, supplement, or procedure available today can eliminate it. But the picture is more nuanced than that blunt answer suggests: antiviral medications can dramatically reduce outbreaks and lower the chance of passing the virus to a partner, and genuine cure research is underway for the first time.
Why the Virus Can’t Be Cleared
HSV-2 is unusually good at hiding. After the initial infection, the virus travels along nerve fibers and settles into clusters of nerve cells near the base of the spine called the sacral dorsal root ganglia. Once there, it shifts into a dormant state called latency. In this state, the virus barely produces any proteins. Instead, it generates molecules called latency-associated transcripts that accumulate in the nuclei of infected neurons and essentially keep the virus parked in hibernation mode.
This is the core problem. Your immune system is effective at fighting HSV-2 when it’s active on the skin or mucous membranes, but it cannot detect or reach the virus while it’s latent inside nerve cells. The nervous system is partially shielded from immune surveillance, and the virus produces so little of itself during latency that there’s almost nothing for immune cells to recognize. Periodically, the virus reactivates, travels back down nerve fibers to the skin, and either causes visible sores or sheds invisibly before the immune system pushes it back into dormancy.
What “Getting Rid of It” Really Means Day to Day
While you can’t eliminate HSV-2, you can suppress it to the point where it has minimal impact on your life. Daily antiviral therapy reduces the frequency and severity of outbreaks, cuts the amount of time the virus is active on the skin, and lowers transmission risk to sexual partners. For many people on suppressive therapy, outbreaks become rare or stop entirely.
The standard options are valacyclovir (once or twice daily), acyclovir (twice daily), or famciclovir (twice daily). These drugs all work the same way: they block the virus from copying itself when it tries to reactivate. They don’t touch the latent virus sitting quietly in your nerve cells, which is why the infection returns if you stop taking them.
A landmark study published in the New England Journal of Medicine found that daily valacyclovir reduced transmission to an uninfected partner by 48%. Symptomatic infections in partners dropped by 75%. Combined with consistent condom use, the risk of passing HSV-2 to a long-term partner falls substantially. These numbers matter most for people in relationships where one partner has the virus and the other doesn’t.
Asymptomatic Shedding: The Hidden Factor
One reason HSV-2 is so widespread is that the virus can be present on the skin with no visible symptoms. Research tracking daily swabs from people with HSV-2 found that the virus was detectable on about 10% of days even in people who had never noticed an outbreak. Among those with recognized symptoms, subclinical shedding occurred on roughly 13% of days. In both groups, the vast majority of shedding days involved no visible lesions at all.
This means you can transmit HSV-2 without knowing you’re doing so, and it’s the main reason the virus is so common. The World Health Organization estimates 520 million people aged 15 to 49 worldwide are living with HSV-2, about 13% of the global population in that age range. Suppressive antiviral therapy reduces shedding, but it doesn’t eliminate it completely.
Health Risks Worth Knowing About
For most people, HSV-2 is a manageable skin condition. Outbreaks tend to become less frequent over the years, and many people experience only mild or infrequent episodes. But the virus does carry some less obvious risks.
HSV-2 roughly doubles the risk of acquiring HIV if you’re exposed to it. One large study found an adjusted hazard ratio of 2.2, meaning HSV-2 positive individuals were about twice as likely to contract HIV compared to those without the virus. The likely reason: HSV-2 causes microscopic breaks in the genital skin and attracts the very immune cells that HIV targets, creating an easier entry point. This makes HSV-2 management especially important in areas where HIV is prevalent.
Neonatal herpes, though rare, is the other serious concern. A mother experiencing an active outbreak during delivery can transmit the virus to the baby, potentially causing severe illness. This is managed through antiviral therapy in late pregnancy and, when necessary, cesarean delivery.
Blood Test Accuracy and Diagnosis
If you’ve been tested for HSV-2 with a blood test, it’s worth understanding what the results mean. The standard IgG blood test looks for antibodies your immune system produces in response to the virus. The FDA has warned that these tests can produce false positive results, particularly when the result falls in a “low positive” range near the test’s cutoff value. If your result is in that borderline zone, confirmatory testing with a different method is a reasonable next step before accepting the diagnosis.
Treatments in Development
Two areas of research are generating the most attention: vaccines and gene therapy.
Moderna’s mRNA-1608 is a vaccine currently in a phase 1/2 trial involving 365 participants, with results expected by mid-2025. In animal studies, it reduced genital disease by 85 to 100% and achieved full survival against lethal viral doses. Several other candidates are also in clinical trials, including a live-attenuated vaccine from Rational Vaccines and a DNA-based vaccine from Anteris Technologies. A new class of antiviral called pritelivir, which works through a completely different mechanism than existing drugs, is in a phase 3 trial and may offer an alternative for people whose virus has become resistant to standard medications.
The most ambitious work is happening at Fred Hutch Cancer Center, where researchers are using gene editing technology to go after the latent virus directly. The approach delivers molecular scissors into nerve cell clusters to physically cut apart the viral DNA hiding there, either damaging it beyond repair or removing it entirely. The team has shown progress in laboratory studies with HSV-1 and is actively adapting the technology for HSV-2, with plans to move toward clinical trials. If this approach works in humans, it would be the first true cure, not just suppression but actual elimination of the virus from the body.
None of these are available yet, and the timeline from promising research to approved treatment is measured in years. But the field is more active than it has ever been, and the biological tools needed to potentially cure HSV-2 now exist in the laboratory.